Current Legislation Search

SB465-FN

Bill Details

Title: classifying xylazine as a schedule III controlled drug.

Sponsors: (Prime) Gannon (R), Abbas (R), Birdsell (R), Carson (R), Rochefort (R), McConkey (R), Lilli Walsh (R), Vose (R), Roy (R), Rhodes (R)

LSR Number: 26-2002

General Status: SENATE

Senate:

Committee: Judiciary

Floor Date: 3/5/2026

Status: CONSENT CALENDAR REPORT FILED

Documents

Subscribe To SB465-FN

Docket

Bill Versions

Introduced [PDF]

Amendments

2026-0842s [PDF]

Hearing Reports

Roll Calls

No House Roll Calls

No Senate Roll Calls:

Bill Docket

Body

Description

Introduced 01/07/2026 and Referred to Judiciary; SJ 1

Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A

Committee Report: Ought to Pass with Amendment #2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8